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Accumulating Data to Optimally Predict Obesity Treatment
(ADOPT): Recommendations from the Biological Domain
Michael Rosenbaum 1, Tanya Agurs-Collins2, Molly S. Bray3, Kevin D. Hall 4, Mark Hopkins5, Maren Laughlin4,
Paul S. MacLean6, Padma Maruvada6, Cary R. Savage7, Dana M. Small8, and Luke Stoeckel4
Background: The responses to behavioral, pharmacological, or surgical obesity treatments are highly
individualized. The Accumulating Data to Optimally Predict obesity Treatment (ADOPT) project provides a
framework for how obesity researchers, working collectively, can generate the evidence base needed to
guide the development of tailored, and potentially more effective, strategies for obesity treatment.
Objectives: The objective of the ADOPT biological domain subgroup is to create a list of high-priority bio-
logical measures for weight-loss studies that will advance the understanding of individual variability in
response to adult obesity treatments. This list includes measures of body composition, energy homeostasis
(energy intake and output), brain structure and function, and biomarkers, as well as biobanking procedures,
which could feasibly be included in most, if not all, studies of obesity treatment. The recommended high-
priority measures are selected to balance needs for sensitivity, specificity, and/or comprehensiveness with
feasibility to achieve a commonality of usage and increase the breadth and impact of obesity research.
Significance: The accumulation of data on key biological factors, along with behavioral, psychosocial,
and environmental factors, can generate a more precise description of the interplay and synergy among
them and their impact on treatment responses, which can ultimately inform the design and delivery of
effective, tailored obesity treatments.
Obesity (2018) 26, S25–S34. doi:10.1002/oby.22156
Introduction
Weight loss provokes coordinated changes in multiple energy
homeostatic systems which culminate in disproportionately increased
energy intake (EI) and decreased energy expenditure (EE) (1,2). The
extensive interindividual variability in responses to weight loss (3)
and treatments differentially targeting these systems (4,5) suggests
that treatment could be improved via better understanding of the
biological factors mediating energy balance (6,7).
The NIH-sponsored Accumulating Data to Optimally Predict obesity
Treatment (ADOPT) Core Measures Project (8) aims to advance
adult obesity medicine in the face of this individual variability in
treatment responses (9). ADOPT is designed to provide investigators
with tools to generate an evidence base consisting of common meas-
ures across the following four domains: behavioral, biological,
environmental, and psychosocial, which can enhance interdiscipli-
nary research and advance understanding of the sources of response
variability, depicted in the ADOPT Working Model.
The biological domain subgroup of the ADOPT working group was
tasked with recommending core measures relevant to the “constructs”
of body composition, energy balance, biomarkers, brain structure and
function, and biobanking, as previously designated by the full ADOPT
working group. The uniform reporting of common measures can
increase the impact and generalizability of the combined research
body. Further information regarding each construct and measure
described below is available at the ADOPT Core Measures Workspace
in the Grid-Enabled Measures (GEM) database (https://www.gem-
measures.org/workspaces/ADOPT), which is also a venue for discus-
sions that help to build consensus around common measures.
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Identification of Biological Measures
In an effort to create a list of measures of relevant biological con-
structs that could be employed across most, if not all, clinical human
obesity studies, several factors were considered in the selection of
the methods (designated as “measures”) best designed to evaluate
each construct given the constraints of human weight-loss trials.
These included (1) the strength of the current evidence relating each
measure to relevant constructs and weight-loss outcomes, (2) the
measure’s validity and reliability, (3) the feasibility of widespread
use of the measure, (4) the measure’s burden to investigators (cost,
administration, availability) and subjects (time and invasiveness),
and (5) the measure’s applicability to small (<50 participants), mod-
erate (50-200 participants), and large (>200 participants) studies.
In many cases, the “gold standard” measures were not the most
practical within the feasibility constraints of many weight-loss trials.
Recognizing the frequent dichotomy between precision and practi-
cality, we provide two classifications of measures within the con-
structs. “Recommended” measures are those that should be feasible
and cost-effective in all obesity-related clinical trials. “Suggested”
measures are those that should be feasible and cost-effective in
many, if not most, clinical trials and, if possible, should be per-
formed in addition to the recommended measures. Except as other-
wise noted (e.g., for targeted genetic studies), all measures outlined
below should be obtained at baseline and at other time points (e.g.,
during and after an intervention) in each study.
Body Composition
Within the area of body composition, we included both anthropo-
metric and bioelectrical impedance measures to allow for the assess-
ment of body fat content, central versus peripheral fat distribution,
and visceral versus subcutaneous fat distribution in a manner that
can be integrated across previous and future studies (10). It is likely
that this recommendation will change going forward, as more inves-
tigators use recommended measures of body fat content (see below).
Anthropometry
Anthropometry includes the assessment of height, weight, and calcu-
lated BMI (recommended) as well as central fat mass (FM) and the
relative distribution of fat in central and peripheral fat depots by
waist and hip circumferences and calculated waist-to-hip ratio
(WHR) (recommended). The feasibility of anthropometry permits
easy frequent measurement (at least every 1 to 3 months in the ini-
tial phases of weight-loss trials), which is necessary to document
early responses (1 to 2 months) to surgical (11,12) and nonsurgical
(13,14) interventions as predictors of long-term success.
However, together BMI, sex, and age only explain approximately
50% to 60% of the variance in percent body fat as measured by dual
energy x-ray absorptiometry (DXA) (suggested), which is the “gold
standard” (15), and anthropometry is clearly less accurate than bio-
electric impedance spectroscopy (BIS), DXA, magnetic resonance
imaging (MRI), and BodPod (see below). The accuracy of BMI is fur-
ther diminished in participants with increased fractional lean body
mass, such as athletes with very high muscle mass, (e.g., weightlifters)
(16), or increased fractional FM, such as the elderly. BMI does not
assess FM and fat-free mass (FFM), both of which are important
determinants of EE and EI, and different interventions may differen-
tially affect body composition (FM and FFM) and weight (16).
It is recommended that both waist circumference and WHR are col-
lected in all adult studies (17) because both the absolute amount of
central fat (17,18) and the relative amount of fat distributed in cen-
tral versus peripheral fat depots (19,20) have been shown to be pre-
dictive of multiple adiposity-related comorbidities and may affect
intervention response (21-23). Both of these measures have been
reported to correlate closely with visceral and subcutaneous adipose
tissue measured by DXA (suggested) or MRI (24,25). To minimize
variability in WHR, it is critical that investigators utilize uniform
landmarks, with waist circumference measured at the iliac crest and
hip circumference measured at the level of the trochanters as uti-
lized by the National Center for Health Statistics in National Health
and Nutrition Examination Survey studies (26). It should be noted
that the abdominal circumference measured at the midpoint between
the inferior border of the ribcage and the superior aspect of the iliac
crest has been reported to be a better correlate of central adiposity
in some studies (27). However, the NIH method is recommended to
allow for better comparisons with existing National Health and
Nutrition Examination Survey and other data.
Anatomic fat storage
Anthropometry fails to distinguish subcutaneous from visceral fat,
which has been reported to be correlated with the risk for metabolic
syndrome, cardiovascular disease, and several malignancies (28), and
the relative distribution of visceral and subcutaneous fat varies signifi-
cantly by gender and between ethnic and/or racial groups (29). Specif-
ically, it is recommended that all studies include more direct measures
of FM by BIS (30), which is a noninvasive and inexpensive type of
bioimpedance to assess body composition that can be utilized in stud-
ies of any size or duration. BIS is comparable with the single-
frequency devices used in bioimpedance analysis (conventionally
denoted as BIA) in terms of subject burden and cost. The multiseg-
mental, multifrequency BIS device allows for the identification of
more components of bioimpedance (capacitance, resistance, etc.) than
single-frequency bioimpedance analysis devices, and BIS measures of
extracellular/intracellular resistance have been reported to be signifi-
cantly correlated with intraabdominal FM measures by computed
tomography scans (31). BIS has also been reported to correlate better
with FM than BMI and with visceral and/or intraabdominal fat (meas-
ured by MRI) than waist circumference or WHR (32). Overall, BIS
has been reported to explain 80% to 90% of the variance in FM and
visceral fat and 50% to 55% of the variance in intraabdominal fat by
DXA and/or MRI (32,33). Despite the advantages of BIS, it has been
reported to underestimate FM and overestimate FFM, especially in
males (33), and BIS can be less reliable when the hydration status of
FM and FFM are uncertain (e.g., in children, individuals with edema,
and postbariatric surgery patients). In addition, there are multiple BIS
systems available that have not been crossvalidated. It is therefore
essential to always report the exact BIS system utilized.
The addition of BIS will allow for the integration of data from mul-
tiple studies and further validation of this approach. Though BIS
provides the best option for the assessment of body composition,
when balancing the value of the data with the cost and participant
burden in large clinical trials, this recommendation does not pre-
clude the use of more accurate or precise suggested measures of
body composition such as DXA, MRI, or quantitative magnetic
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resonance spectroscopy. It is anticipated that the acquisition of BIS
data along with other suggested measures of body composition in
some studies will provide a large data set that can be utilized to bet-
ter define the precision of BIS in different populations.
Energy Balance
The relative long-term constancy of body weight and the overall
lack of success of nonsurgical interventions in long-term weight
reduction suggests that, at usual weight, EI and output are “coupled”
and vary directly to maintain energy stores. Once weight is per-
turbed, this coupling is lost, and EI and energy output now vary
inversely to “defend” previous body energy stores (2,34). There is
large interindividual variability in EI and EE (including cardiorespir-
atory fitness [CRF], which is an important determinant of exercise
recommendations) and, of course, adherence before, during, and
after weight change (3,23,35-37). A better understanding of this var-
iability is likely to identify certain energy homeostatic phenotypes
that are predictive of individualized best practice recommendations.
EE
Total EE (TEE) is composed of resting EE (REE), the thermic effect
of feeding (TEF), and nonresting EE (NREE) (38), each of which is
likely to change in weight-loss studies. Direct and indirect objective
measures for these variables present challenges for large clinical
weight-loss trials because of their expense, participant burden, and
feasibility. Because of these limitations, it is recommended that
measures of TEE and its components be calculated.
Calculated REE should be acquired with the Mifflin-St. Jeor equation
(recommended) (39), which is best correlated (R2 5 0.80-0.85) with
calorimetric measures of REE (39) and superior to other less-studied
or more population-specific equations (40). The following are the
Mifflin-St. Jeor equations: for males, REE (kilocalories per day)-
5 10 3 weight (kilograms) 1 6.25 3 height (centimeters) 2 5 3 age
(years) 1 5; for females, REE (kilocalories per day) 5 10 3 weight
(kilograms) 1 6.25 3 height (centimeters) 2 5 3 age (years) 2 161.
It should be noted that the Mifflin-St. Jeor equation may also have
limitations in its generalizability. Equations for individuals who are
transgender, intersex, have abnormal numbers of X or Y chromo-
somes, or who have undergone or are undergoing surgical or hormo-
nal therapy relevant to gender have not as yet been derived (41).
The increasing attention to gender medicine and gender-specific bio-
logical variation in human metabolic disease should yield an
expanded list of calculations going forward.
In lieu of directly measuring NREE, it is recommended that a
questionnaire-based assessment of Physical Activity Level (PAL) be
acquired (42). PAL is defined as TEE/REE, and the questionnaire-
derived PAL was chosen because of its simplicity, its validation by
correlation with PAL measured by calorimetry, and its applicability
across multiple studies. This questionnaire provides a self-evaluation
of physical activity during work and leisure activities. The calcu-
lated REE and PAL can then be used to derive a calculated TEE
(TEE 5 PAL 3 REE).
The working group readily acknowledges that other direct and indi-
rect measures can provide more accurate and precise measures of
TEE, its components, and metabolic adaptation in response to treat-
ment (43) but are not feasible in many weight-loss trials because of
the expense and required specialized equipment (38,44). If possible,
the calorimetric measurement of REE in the overnight fasted state
by using a metabolic cart or room indirect calorimeter to measure
rates of carbon dioxide production (VCO2) and oxygen consumption
(VO2) is suggested. The VCO2/VO2 ratio provides an index of the
relative mixture of metabolic fuels being utilized. Similarly, doubly-
labeled water can be used to measure TEE in the free-living envi-
ronment, and whole-room indirect calorimetry chambers can be used
to provide robust objective estimates of TEE, NREE, and REE.
Though these approaches can also be utilized to acquire TEF with
the appropriate feeding study design, TEF is neither recommended
nor suggested across all studies because of the necessary complexity
of these designs coupled with the relatively small contribution of
TEF to TEE and adaptive thermogenesis (3).
EI
Under static conditions of body weight and composition stability, EI
must be equal to TEE. EI steady state (recommended) refers to EI
when body composition and mass are not changing over time and
can be presumed equal to the calculated TEE (45). It should be
noted that this does not include or account for variations in diet
composition or the possible effects on the partitioning of stored
calories (see the body composition section) that might occur, for
example, as a result of weight loss with a resistance training compo-
nent (increased partitioning of stored calories as FFM) versus aero-
bic training (46). During dynamic periods of weight change
(EI 6¼EE), measuring EI is more difficult. Self-reported EI measures
have been shown to be inaccurate (47) but changes in EI (recom-
mended) during such periods can be mathematically modeled with
measures of EE and body composition dynamics (33). This model
has recently been validated against the intake-balance method in a
2-year calorie-restriction experiment in 140 people of varying age
and BMI (48), and it requires only baseline anthropometric and
demographic information along with repeated body weight measure-
ments over the course of the intervention. There are assumptions
underlying this model, such as the stability of REE and PAL. More
frequent body weight measurement increases the precision of the
calculated changes in EI over time, and physical activity time course
data (e.g., from actigraphy measurements) can also be incorporated
to account for changes in NREE. The full description of this calcula-
tion, including MatLab Code information, can be found at the GEM
website (https://www.gem-measures.org/workspaces/ADOPT).
The estimation of the average EI over an extended duration is
ideally calculated by using the intake-balance method involving
body composition measurements along with repeated TEE measure-
ments by using doubly labeled water (49); these procedures are,
unfortunately, impractical for larger weight-loss studies. Depending
upon the duration and types of weight-loss intervention, and partici-
pant age and gender, calculated EI based on TEE and weight or
body composition change has accounted for between 20% and 60%
of the variance in EI calculated by using the intake-balance method
(suggested) as described above (48).
CRF
CRF varies significantly between individuals and may modify
responses to obesity treatment either directly or via compliance with
Supplement Obesity
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exercise recommendations (50). CRF is also significantly correlated
with mortality and comorbidity risk, independent of body fatness
(51). Though the gold standard for CRF is an ergometric VO2max
test, an approximation can be made from resting heart rate or an
alternative submaximal fitness test. Resting heart rate was selected
as a recommended measure because it is easy and inexpensive to
perform and has been reported to explain about 20% of the variance
in CRF (52) using multiple different equations and calculations. The
3-minute step test has been reported to explain 50% to 90% of the
variance in fitness by treadmill testing but may not be practical for
larger studies, and it is therefore suggested rather than recommended
(53,54). For subjects who are unable to perform the step test because
of orthopedic or fitness issues, a simpler version using a corridor
walk may be substituted (55).
Brain Structure and Function
Obesity-associated alterations in brain structure and function (56,57)
have been correlated with weight loss and regain in behavioral and
bariatric surgery trials (56,58), with limited data regarding other
treatments. Incentive motivation, reward learning, and executive
function (including working memory) (58) are the neurocognitive
constructs most predictive of treatment outcomes. These functions
are largely mediated by the dopaminergic fronto-striatal (reward/
motivation), fronto-parietal (executive function), and hippocampal-
amygdala (learning and memory) systems, which operate as both
independent and interdependent networks (59). Emerging data has
also indicated that related neural systems (interoceptive and salience
networks) could be important for weight outcome prediction (60).
This manuscript focuses on brain structure and function rather than
the affected neurocognitive constructs discussed in the ADOPT
psychosocial domain (61). The current gold standard measures are
MRI to assess structure and blood oxygen-dependent functional MRI
(fMRI) to assess function. FMRI can identify the (1) neural sub-
strates that execute behaviors in response to environmental demands
and (2) functionally linked intrinsic neural networks that can be
assessed in the absence of external, environmental demands (i.e.,
resting state fMRI). The measurement of resting-state connectivity is
feasible in large multisite studies and, when integrated with other
measures (e.g., cognitive, psychosocial, other biomarkers), can
define mechanisms and neuropsychological subtypes that may pre-
dict responses to treatment (62) even though correlations of resting-
state fMRI in specific single brain regions with behaviors are rela-
tively low (63-69).
Because of the cost and burden to both the participants and research-
ers, resting-state fMRI scans are only suggested when feasible. Analy-
ses of these fMRI data should include the assessment and comparison
across several networks representing the neural systems described
above. The suggested MRI/fMRI protocol includes (1) anatomical
MRI for structure (volume, density, shape, cortical thickness) and to
aid in preprocessing of the fMRI data, (2) diffusion MRI (white matter
tractography or structural connectivity), and (3) resting-state func-
tional connectivity MRI. Given that resting-state functional connectiv-
ity MRI may be sensitive to the internal state, collecting data about
the participant’s last meal and the subjective experience of the internal
state (hunger, satiety) is suggested (61). Resting-state studies in fast-
ing and fed states will provide insights into brain areas related to meal
initiation and cessation. The value of fMRI is significantly increased
through the integration with neurocognitive and psychosocial meas-
ures (61) and biomarkers of EI (e.g., gut peptides) and EE (e.g., leptin
and thyroid hormones) described below.
Humoral Biomarkers
Biomarkers can provide information about the potential mechanisms
by which information regarding nutreint availability, energy stores,
and energy balance are communicated to central nervous system
tracts regulating energy homeostasis as well as provide valuable
insights into adiposity-related comorbdities. Biomarker significance
is influenced by whether subjects are at weight homeostasis, are
weight-reduced, or are in the process of weight gain or loss. Some
of the recommended biomarkers (e.g., leptin) predictably and coor-
dinately change in response to calorie-restricted weight loss in a
manner that would elevate appetite and suppress EE (1). Baseline
measures for some recommended biomarkers (e.g., leptin, total ghre-
lin) are predictive of weight regain (70,71) in some, but not all,
studies (72). The potential value and/or cost of these measures at
baseline, after weight loss, and after a period of weight maintenance
is considered high, given the low subject burden (i.e., a blood draw)
and commercial availability of the assays.
Energy homeostasis
A number of adipocyte-derived hormones yield valuable data
regarding factors that may affect or represent energy stores and bal-
ance. As exemplified by leptin (recommended) (73), response to any
intervention may depend upon whether the participant is being
treated to promote weight loss or prevent weight regain. Therefore,
biochemical assessments relevant to energy balance and/or affecting
EI and energy output are extremely relevant.
Leptin is secreted by adipose tissue, reflects both adipose tissue stores
and energy balance, and is recommended. At baseline weight, circulat-
ing leptin concentrations are directly proportional to FM, while during
caloric restriction, the leptin/FM ratio may be severely decreased ver-
sus only mildly diminished following weight loss (73). A low ratio of
leptin to FM may therefore be an indicator of undernutrition, while an
unusually high ratio may suggest leptin resistance.
The measurement of fasting levels of the pancreatic peptide amylin
is recommended, not only for its effects on nutrient utilization by
inhibition of postprandial glucagon, but also because it reduces EI
by promoting satiation and attenuates the disproportionate decline in
EE that typically occurs during and following weight loss; it thus
serves as a marker of weight response (74). In rodent studies, amylin
receptors are located within the brainstem as well in multiple other
organs, and exogenous amylin acts synergistically with leptin as
well as glucagon-like peptide 1 (GLP-1), peptide YY (PYY3-36), and
other anorexiant molecules (75). In human studies, coadministration
of amylin with leptin has been shown to enhance weight loss during
caloric restriction (76).
Adiponectin, particularly high-molecular-weight (HMW) adiponec-
tin, is recommended because of its positive association with cardio-
vascular fitness and insulin sensitivity and its negative association
with the secretion of multiple proinflammatory cytokines. During
caloric restriction, adiponectin levels increase disproportionately to
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the decrease in FM. The multifunctional nature of adiponectin and
its potentially pivotal role in mediating comorbidity risk make it a
worthwhile and relatively inexpensive test to perform; analyses of
high-molecular-weight and low-molecular-weight adiponectin is rec-
ommended in all studies (77,78).
Thyroid hormones
Measures of key components of thyroid hormones (thyroid-stimulat-
ing hormone, thyroxine (T4), and the free T4 Index) are recom-
mended because of their known role in regulating energy balance.
Diet-induced weight loss is accompanied by a decline in thyroid-
stimulating hormone, Triidothyronine (T3), and T4 similar to “sick
euthyroid syndrome” (79,80), and thyroid-hormone repletion in
weight-reduced individuals has recently been reported to resolve
some of the peripheral adaptive responses thought to drive weight
regain (Rosenbaum M, Goldsmith R, Haddad F, et al., unpublished
data, 2018) in a manner similar to what is seen following thyroid
repletion in hypothyroid individuals (81,82). Other factors com-
monly measured when assessing thyroid status (T3, reverse T3)
present a significant burden for researchers because of the expense
of these assays and are suggested only when resources are available.
Hunger/satiety signals
Hunger and/or satiety hormone levels change in response to meals
and collectively provide surrogate signals for nutrient availability. A
number of gut-derived peptides, including ghrelin, GLP-1, and
PYY3-36, affect appetite (83) and coordinately change in response to
calorie restriction (1). Baseline total ghrelin levels are predictive of
weight loss (70), and meal responses of PYY3-36 and GLP-1 have
been associated with successful reduced-weight maintenance (84).
Such studies provide examples of how these peptides could be valu-
able in modeling treatment outcomes. Though postprandial responses
of these hormones have provided the most pertinent information for
predicting treatment responses, meal challenges were judged as too
great of a burden on both participants and the researchers. The mea-
surement of fasting total ghrelin, GLP-1, and PYY3-36 is recom-
mended for all weight-loss studies as the best compromise between
feasibility and informational value. Other gut peptides with similar
actions were considered for predicting treatment outcomes, including
cholecystokinin and glucagon inhibitory peptide, but the added value
was deemed insufficient because of the greater assay difficulty and
expense and the likelihood of collinearity with those already recom-
mended. Plasma AgRP has been suggested as a biomarker of hypo-
thalamic melanocortin activity, which could reflect downstream
activity of the hunger and satiety signals even though there is only
limited evidence for it as a biomarker. AgRP is linked to insulin
sensitivity during and after weight loss (85), suggesting that this
molecule may provide insights relevant to other biomarkers as well
as brain function. For these reasons, measures of cholecystokinin,
glucagon inhibitory peptide, AgRP, and postprandial responses of all
of these hunger/satiety signals were suggested only when it is feasi-
ble and resources are available. It should also be noted that properly
processed and stored samples can be biobanked (see below) for
future analyses if cost limitations are prohibitive in a given study.
Nutrient status
Nutrient-sensing systems in peripheral tissues and in specific regions
of the hypothalamus exist that convey signals of nutrient availability
for appetite regulation and, therefore, serve as indices of nutrient
status. Fasting levels of glucose, nonesterified fatty acids (NEFA),
and triglycerides (TG) are recommended at baseline, during weight
loss, and after weight loss. Glucose, NEFA, and TG are the primary
nutrients in circulation, and all three respond to calorie-restricted
weight loss (1). TG are also thought to affect the sensitivity of the
brain to peripheral hormones through their effects on blood brain
barrier transport. These metabolites consistently change with diet-
induced weight loss in a manner that could elevate appetite (1), and
the assays are relatively inexpensive and commonly used in clinical
research. As with the gut peptides, the measuring postprandial
responses of these molecules is not feasible in all studies. For these
reasons, acquiring postprandial responses in glucose, NEFA, and TG
is suggested only when resources are available.
Metabolic function
Metabolic (anabolic and catabolic) function, insulin sensitivity, and
glucose control (recommended) could serve as mediators or modera-
tors of treatment responses and have been shown to influence patterns
of weight loss and weight-loss maintenance (71,86). Some studies
have suggested that diet macronutrient content may influence weight-
loss intervention efficacy according to the level of insulin sensitivity
(87). The group recommends that fasting levels of insulin, glucagon,
and glycosylated hemoglobin (HbA1c) be measured before, during,
and after weight loss. Along with the metabolite data, these measures
can be utilized to calculate indices of insulin sensitivity and secretion
(homeostatic model assessment of insulin resistance and homeostatic
model assessment for b-cell function; HOMA-IR, HOMA-b recom-
mended) (88). There was some discussion that an oral glucose toler-
ance test should also be included to provide a more accurate assess-
ment of glucose control. However, there was insufficient evidence
that the oral glucose tolerance test would provide sufficient added
value over the other surrogate biomarkers of metabolic function for
weight-loss outcomes, and it is suggested only when resources are
available. There are more invasive measures of insulin secretion and
sensitivity (hyperinsulinemic-euglycemic clamp, intravenous glucose
tolerance test, etc.) and more comprehensive measures of key aspects
of metabolic flexibility, but these tests are not feasible for all large-
scale clinical weight-loss trials.
Inflammation
We also recommend assessment of the inflammatory markers tumor
necrosis factor-alpha, C-reactive protein, and interleukin 6 (IL-6) in
the fasted state before, during, and after weight loss. These inflam-
matory factors could mediate or moderate the impact of metabolic
dysfunction on treatment outcomes. Tumor necrosis factor-alpha is a
true adipokine and is elevated in obesity (89). C-reactive protein is
made in the liver, largely in response to IL-6, which is produced in
liver and skeletal muscle. These molecules represent three different
sources of inflammatory markers and are all associated with the sub-
sequent risk for type 2 diabetes (90) and cardiovascular disease (91).
By using network modeling that combined biological, gut micro-
biota, and environmental factors relevant to weight trajectories,
baseline levels of IL-6 and plasma insulin most accurately classified
individuals who did or did not lose weight and maintain weight loss
(92). The global inflammatory status could be assessed by larger
panels, but these biomarkers should be sufficient at present to exam-
ine the strength of the link between inflammation and treatment
outcomes.
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Biobanking Tissues
The molecular mechanisms underlying the physiological opposition
to weight loss and reduced weight maintenance (2), and the possibil-
ity that they mimic the “preobesity” state in which someone is
genetically and physiologically “at risk” for weight gain, have not
been comprehensively elucidated. A uniform methodology across
weight-loss studies for collecting and storing biological samples to
measure RNA and DNA from cells in the blood as well as exosomal
and free RNAs would provide a valuable resource for interrogating
the molecular underpinnings of weight gain, weight loss, and weight
regain. For reasons discussed below, biobanking of whole blood and
its components (plasma, serum, etc.) with appropriate stabilization
(e.g., protease inhibitors) is recommended as the best balance of fea-
sibility, cost, participant burden, expertise and/or equipment needed
to collect and process the samples, and relevance to weight-loss
physiology.
Whole Blood
Though many different kinds of bodily fluids and tissues can be col-
lected with varying degrees of difficulty, expense, and value (Figure 1),
whole blood gives the greatest advantages for ease and the potential
amount of relevant information it can provide. Though sample collec-
tion is invasive and can be challenging for individuals with obesity, par-
ticipant burden and the need for expertise to collect whole blood sam-
ples is offset by the ability to use samples to interrogate circulating
proteins, metabolites, and noncoding RNAs, which have been identified
as relevant to energy homeostasis or which may one day be identified.
In addition, both red and white cells can be used to examine cellular
processes related to a host of outcomes, including glycosylation,
immune response, and metabolism.
Functional Analysis/Genetic Screening
In addition to the assessment of the biomarkers described above,
both RNA and DNA can be extracted from whole blood for a global
assessment of genomic variation, gene expression, and epigenetic
modification to ultimately allow a uniform characterization of the
contribution of genes across weight-loss studies. This genetic screen-
ing would comprise a powerful resource for understanding the
genetic and epigenetic molecular underpinnings of variability in
weight loss. This type of screening is suggested at present because
of resource limitations, but, as its feasibility and cost becomes more
reasonable, we fully expect that it will become a recommended
assessment. The biobanking recommendation of whole blood will
Figure 1 Review of selection criteria for different tissues that could be biobanked. Whole blood is clearly the best fit for these criteria,
though other tissues should not be eliminated if available depending upon their relevance to the specific study. Collection costs include creation
of sample aliquots; measured markers include metabolites, nucleotides, and proteins.
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ensure that tissues will be available to pursue future genetic studies,
even if resources are not immediately available. Sequence variations
in multiple genes have been tied to energy balance and treatment
outcomes in weight-loss studies, which could serve to focus the
analysis. These genes include BDNF, DRB3, FTO, GNPDA2,
LYPLA, MC4R, MTCH2, and MTIF3, while other less-studied genes
(NEGR1, PLIN, and RANK, LEP and LEPR) may also provide rele-
vant information about the variability in treatment response. Studies
demonstrating significant intrapair correlations (r 5 0.75-0.85) in
response to weight-loss interventions among identical twins (93) and
genetic predictors of weight-loss response to various interventions in
large clinical trials (94,95) suggest that different single-nucleotide
polymorphisms (SNPs) may be predictive of the magnitude of
weight loss versus regain depending upon the nature of the interven-
tion and subject population. In the future, the use of array-based
chips with highly informative dense SNP content, including
genome-wide tag SNPs found across diverse world populations and
customizable markers for use in large weight-loss studies, can be
used as a cost-effective means of creating a well-powered cohort of
individuals in which the genetic underpinnings of weight loss can be
examined for multiple traits and outcomes.
Other Tissue Considerations
Biobanking of other tissues is also suggested depending upon
resource availability. Buccal (cheek) cells (suggested) are easy and
inexpensive to collect via cytobrushes, which involves simply swab-
bing the cheeks and gutters of the mouth to collect sloughed cells.
Both DNA and RNA can be extracted from buccal cells (96), though
there is a limited range and relevance of markers that can be meas-
ured (96). Similar limitations are inherent in the use of saliva sam-
ples (suggested). Urine and stool samples (suggested) are relatively
easy and inexpensive to obtain, though the relevance of urinary bio-
markers to weight loss may be limited. Stool (97) can be used to
examine the gut microbiome, gut absorption, and markers of metab-
olism. Although transplantation of the microbiome from obese or
lean mice or humans to gnotobiotic (germ-free mice) clearly affects
somatotype, the role of the microbiome as a cause or potential thera-
peutic target in human obesity is not clearly established (98). Cur-
rent research in the NIH Human Microbiome Project (HMP) (99)
directly addresses these issues, and investigators are suggested to
contact the NIH directly for microbiome banking information.
Tissue biopsies allow for the unbiased genomic, epigenetic, and pro-
teomic interrogation of key metabolic tissues (skeletal muscle, adi-
pose) involved in the regulation of energy balance. Because of the
burdens placed on subjects and investigators, the collection of spe-
cific tissue biopsies is suggested for studies with specific objectives
directed at elucidating molecular mechanisms or generating the evi-
dence as to how these tissues could serve as mediators or modera-
tors of treatment outcomes.
Conclusions
The ADOPT biological domain subgroup was tasked with identify-
ing feasible measures of biological constructs (body composition,
energy homeostasis, brain structure and function, blood biomarkers,
and biobanking tissues) that, when used consistently in weight-loss
trials, could serve to explain the variability in treatment outcomes
and lay the foundation for genetic-, epigenetic-, and genomic-based
analyses. Selections (Table 1) were made with the underlying goal
of maximizing the potential to address knowledge gaps in obesity
treatment in conjunction with the other ADOPT domains. It is the
intent of the ADOPT project that these recommendations and sug-
gestions as well as the GEM website will be updated as new infor-
mation becomes available.
It should be emphasized that the recommended measures are not
always the “gold standard,” but they are the ones that are most fea-
sible across numerous different study sizes and population. When
integrated across studies and with the other ADOPT domains, the
recommended measures will facilitate the development of a large
comprehensive database that could be mined to evaluate, propose,
and implement current and future obesity treatments with maximal
efficacy. The recommended and suggested measures are intended to
augment weight-loss intervention studies rather than replace planned
measures.
The strengths and weaknesses of the ADOPT biological domain are
closely intertwined. The main strength is the practicality of the
measures that can be implemented in most, if not all, studies going
forward at little additional expense and inconvenience to investiga-
tors and participants. An additional strength is the intentional malle-
ability of the ADOPT recommendations and suggestions. Regular
modifications of the ADOPT domain manuscripts are anticipated
based on new data and techniques that become available and on
input from the scientific community through the GEM website. The
weaknesses of the recommended and suggested measures are that, to
achieve necessary fiscal and feasibility goals, numerous more sensi-
tive or specific measures are not included. To address these issues,
we would encourage biobanking of serum, plasma, and buffy coats
on as many participants as possible in anticipation of the decreasing
costs and increasing understanding of relevant future assays.O
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